Close Menu

NEW YORK – Molecular diagnostics company Asuragen announced on Monday that it is collaborating with genetic medicines developer Wave Life Sciences to develop and commercialize companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.